Multicenter study to evaluate paxalisib plus gemcitabine for children and young adults with recurrent or progressive AT/RT, where no approved therapies currently exist SYDNEY, Sept....
XCMG Accelerates European Growth with Localized Services, Green Tech, and Strategic Partnerships MUNICH, April 9, 2025 /PRNewswire/ -- At bauma 2025, the world's premier...
MUNICH, April 9, 2025 /PRNewswire/ -- Zoomlion Heavy Industry Science & Technology Co., Ltd. ("Zoomlion"; 1157.HK), a global leader in construction machinery, is showcasing...
AI-powered self-optimizing and self-healing network intelligence enables ISPs to deliver exceptional user experiences, enhance operational efficiency, and reduce churn. SAN ANTONIO, April 9,...
